Current and Future Biomarkers in Multiple Sclerosis.
Current and Future Biomarkers in Multiple Sclerosis.
复制标题
DOI：
10.3390/ijms23115877
复制
发表时间：
2022-05-24
影响因子：
5.6
通讯作者：
中科院分区：
文献类型：
--
作者：
多发性硬化症（MS）是一种使人衰弱的自身免疫性疾病。目前，缺乏对MS进行性形式的有效治疗，部分原因是神经变性的不敏感读出。神经丝轻链（NfL）敏感检测的最新发展使其成为预测MS疾病活动和进展的潜在新生物标志物，为临床试验提供了额外的读数。然而，NfL在除MS之外的其他神经退行性疾病中升高，此外，它还受到年龄、体重指数（BMI）和血容量的混淆。此外，与健康对照相比，血清NfL（sNfL）水平的范围存在相当大的重叠。这些混杂因素证明了仅使用NfL作为监测MS患者疾病活动的标志物的局限性。轴突损伤、神经元损伤、神经胶质功能障碍、脱髓鞘和炎症的其他血液和脑脊液（CSF）生物标志物已被研究为MS的可操作生物标志物，并提供了对MS疾病过程的病理学基础的洞察。然而，这些其他生物标志物可能受到与NfL类似的问题的困扰。使用生物信息学方法的生物标志物，包括细胞研究，微RNA（miRNA），细胞外囊泡（EV），代谢组学，代谢物和微生物组可能被证明有助于开发更全面的小组，解决使用单一生物标志物的局限性。因此，需要更多的研究与最新的技术和统计方法，以确定新的和有用的诊断和预后的生物标志物工具在MS。
Multiple sclerosis (MS) is a debilitating autoimmune disorder. Currently, there is a lack of effective treatment for the progressive form of MS, partly due to insensitive readout for neurodegeneration. The recent development of sensitive assays for neurofilament light chain (NfL) has made it a potential new biomarker in predicting MS disease activity and progression, providing an additional readout in clinical trials. However, NfL is elevated in other neurodegenerative disorders besides MS, and, furthermore, it is also confounded by age, body mass index (BMI), and blood volume. Additionally, there is considerable overlap in the range of serum NfL (sNfL) levels compared to healthy controls. These confounders demonstrate the limitations of using solely NfL as a marker to monitor disease activity in MS patients. Other blood and cerebrospinal fluid (CSF) biomarkers of axonal damage, neuronal damage, glial dysfunction, demyelination, and inflammation have been studied as actionable biomarkers for MS and have provided insight into the pathology underlying the disease process of MS. However, these other biomarkers may be plagued with similar issues as NfL. Using biomarkers of a bioinformatic approach that includes cellular studies, micro-RNAs (miRNAs), extracellular vesicles (EVs), metabolomics, metabolites and the microbiome may prove to be useful in developing a more comprehensive panel that addresses the limitations of using a single biomarker. Therefore, more research with recent technological and statistical approaches is needed to identify novel and useful diagnostic and prognostic biomarker tools in MS.
登录
查看更多内容
影响因子：
5.8
作者：
Colucci, M;Roccatagliata, L;Mancardi, Gl
通讯作者：
Mancardi, Gl
DOI：
10.1083/jcb.101.4.1371
发表时间：
1985-10
期刊：
The Journal of cell biology
影响因子：
--
作者：
Binder LI;Frankfurter A;Rebhun LI
通讯作者：
Rebhun LI
DOI：
10.1212/nxi.0000000000000555
发表时间：
2019-05-01
影响因子：
8.8
作者：
Akguen, Katja;Kretschmann, Nicole;Ziemssen, Tjalf
通讯作者：
Ziemssen, Tjalf
影响因子：
29
作者：
Bjornevik, Kjetil;Munger, Kassandra L.;Ascherio, Alberto
通讯作者：
Ascherio, Alberto
影响因子：
5.8
作者：
Brettschneider, J;Petzold, A;Tumani, H
通讯作者：
Tumani, H